AbbVie Inc.(ABBV)— Stock Profile, AI Score & Financials
Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
AbbVie Inc. (ABBV) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ABBV at 72.6/100 on a 32-signal composite quality model, placing it at rank #148 of 2,960 stocks — the top 5% of the AI-ranked universe. ABBV scores in the top quartile across revenue scale (97.6), earnings quality (90.4), free cash flow (82.1). Shareholder dilution risk is elevated at 45.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), AbbVie Inc. reports quarterly revenue of $17.0B, net income of $3.6B, free cash flow of $3.1B. Top institutional holders of ABBV by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. ABBV trades on the NYSE exchange and files with the SEC under CIK 1551152. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ABBV daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AbbVie Inc. directly from SEC EDGAR.
AI Quality Score
72.6/100
AI Rank
#148
Revenue
$17.0B
Net Income
$3.6B
Free Cash Flow
$3.1B
ABBV key financials by period
AbbVie Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$61.2B
$4.2B
24.6%
FY 2024
10-K
$56.3B
$4.3B
16.2%
FY 2023
10-K
$54.3B
$4.9B
23.5%
FY 2022
10-K
$58.1B
$11.8B
31.2%
FY 2021
10-K
$56.2B
$11.5B
31.9%
FY 2020
10-K
$45.8B
$4.6B
24.8%
Institutions holding ABBV
Institutional investors reporting a position in AbbVie Inc. on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-08-03 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Net revenues rose 10.2% to $17.0B as Skyrizi ($5,505M, +24.4%) and Rinvoq ($2,525M, +24.5%) more than offset Humira's 35.9% decline; net earnings reached $3,616M.
Biggest Revenue Drivers
Skyrizi$5,505M+24.4% YoY
Continued strong market share uptake as well as market growth across all indications
Rinvoq$2,525M+24.5% YoY
Continued strong market share uptake as well as market growth across all indications
Biggest Revenue Drivers
Total revenue: $17.0B+10.2% YoY
Skyrizi$5,505M+24.4% YoY
Continued strong market share uptake as well as market growth across all indications
Rinvoq$2,525M+24.5% YoY
Continued strong market share uptake as well as market growth across all indications
Vraylar$1,071M+18.9% YoY
Continued market share uptake and market growth as well as favorable pricing
Botox Therapeutic$1,042M+12.2% YoY
Market growth as well as continued market share uptake
Humira$756M-35.9% YoY
Continued impact of direct biosimilar competition following the loss of exclusivity
Largest Expense Items
Cost of products sold$4,291M
Includes $1.7 billion of intangible asset amortization; decreased amortization lowered fixed costs
Selling, general and administrative$3,632M+12% YoY
Continued leverage from net revenues growth, offset by higher litigation reserve charges
Research and development$2,344M+10% YoY
Increased to support all stages of the company's pipeline assets
Acquired IPR&D and milestones$291M
Down from $823M; prior-year quarter included $350M Gubra and $335M ADARx upfront charges
Margins: Gross margin was 75% of net revenues versus 72% a year ago, increasing primarily due to higher net revenues against lower fixed costs driven by decreased amortization of intangible assets.
Watch Items from the Filing
Three U.S. wholesalers accounted for 82% of total net accounts receivable at June 30, 2026, and substantially all U.S. pharmaceutical product net revenues.
Contingent consideration liabilities reached $27,495M, with a $1.5 billion fair value charge in the quarter driving other expense, net of $1,475M.
Humira fell to $756M from $1,180M on biosimilar competition; U.S. Humira dropped 47.0% to $425M.
Proposed $10.9 billion Apogee acquisition, backed by a new $10.0 billion 364-day term loan facility, against total deficit of $(5,888)M.
Litigation accrual was $1.7 billion; approximately 1,300 Biocell ALCL suits sit in MDL 2921, and Botox was selected for Medicare government-set prices beginning 2028.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
